Africa can’t outsource its deadliest threats
Sovereignty in global health is ultimately about being able to act without hesitation when lives are
on the line. That ability does not come from statements or summits; it comes from infrastructure that works when pressure is highest. High‑containment laboratories sit quietly in the background until they are needed, and then they matter more than almost anything else. If the African Union is serious about preparedness, it must make BSL‑4 capacity a regional priority. Ghana’s experience shows that the resources already exist. What remains is the decision to turn them into something enduring. Global health sovereignty will not arrive fully formed. It will be built—carefully, deliberately, and on African terms.
Global health sovereignty is built, not declared
Global health sovereignty is increasingly invoked across Africa, especially in the aftermath of epidemics, supply-chain failures, and persistent inequities in access to medical countermeasures. Yet sovereignty is not something that can be asserted into existence. It is built, slowly and deliberately, through institutions, infrastructure, and sustained investment in capabilities that allow
Sensitivity: Official Use
countries to act independently when it matters most. Among these capabilities, the ability to safely detect, study, and respond to the world’s most dangerous pathogens is fundamental.
At present, Africa remains dangerously under-represented in global Biosafety Level-4 (BSL-4) laboratory capacity. This is not a marginal technical gap. It is a strategic vulnerability. BSL-4 laboratories are where the most hazardous pathogens are confirmed, characterized, and studied under maximum containment. Without access to such facilities within its own governance structures, the continent remains dependent on external systems at precisely the moments when speed, control, and authority are most critical.
The structural dependence in high-containment science
Globally, BSL-4 laboratories are concentrated overwhelmingly in Europe and North America, with a small number in parts of Asia. Africa hosts only a handful (~2 BSL-4 Labs). This imbalance persists despite the continent’s central role in the ecology of emerging and re-emerging infectious diseases. The result is a recurring pattern: biological samples must be shipped abroad, diagnostics are delayed, and decisions are shaped far from where outbreaks occur.
These are not abstract inconveniences. In outbreak settings, delays translate into lost lives, economic disruption, and public mistrust. If global health sovereignty is to mean anything tangible, this structural dependence has to change.
Why regional, not fragmented, solutions matter
The most practical path forward is not a scatter of national BSL-4 projects, but a regional approach anchored by the African Union. A clear and achievable objective would be to establish at least one BSL-4 laboratory within each African regional bloc, governed collectively and aligned with continental priorities. These facilities would function as shared strategic assets, supporting diagnostics, outbreak response, training, and research across borders.
This is not an untested idea. Europe has long operated BSL-4 laboratories within coordinated networks rather than as isolated national symbols. Africa already pools regulatory authority, disease surveillance, and technical expertise in other domains. High-containment laboratories should follow the same logic. The goal is not proliferation, but sufficiency, sustainability, and trust.
Cost is not the real constraint
BSL-4 laboratories are expensive to build and maintain. Construction alone can exceed USD 100 Million, and operating costs require long-term political commitment. But framing cost as the central barrier is misleading. African governments routinely mobilize comparable sums for infrastructure, energy projects, extractive industries, and defence when priorities are clear.
Sensitivity: Official Use
The real question is whether high-containment biological capacity is recognized as essential national and regional infrastructure. Too often, BSL-4 laboratories are framed as elite scientific projects, disconnected from everyday public concerns. When viewed this way, they struggle to compete for attention and funding. When understood as public goods that protect populations, economies, and ecosystems from biological threat, the case becomes far stronger.
Ghana, gold, and health responsibility
Ghana could offer a particularly instructive example. As one of Africa’s leading gold producers, the country has recently consolidated authority over gold trading and exports through the Ghana Gold Board (GoldBod). Crucially, GoldBod’s mandate includes corporate social responsibility, environmental remediation, and support for health and social development in mining-affected communities.
This matters because the health and environmental consequences of mining, especially illegal and artisanal mining, are profound. Water sources have been contaminated, ecosystems degraded, and communities exposed to heavy metals and respiratory hazards and infections. These are not distant
or hypothetical harms; they are ongoing public health crises.
Directing a portion of GoldBod proceeds toward the construction of a national or regional BSL-4 facility would represent a meaningful shift in how extractive wealth is reinvested. It would transform mineral rents into long-term health security infrastructure. It would link environmental damage to health protection in a concrete way. And it would demonstrate that corporate social responsibility can extend beyond short-term projects to strategic national assets.
Such an investment would not be symbolic. Ghana already has scientific institutions, regulatory experience, and regional credibility that could support a high-containment facility governed to international standards. More importantly, it would demonstrate that African states can finance and govern advanced biological infrastructure on their own terms.
Moving beyond victimhood narratives
This argument does not depend on narratives of victimhood or neglect. Africa does not need to justify BSL-4 capacity by appealing to sympathy or historical grievance. The case is simpler and stronger: the continent is already central to global pathogen emergence, and sovereign capacity is therefore a matter of responsibility as much as self-interest.
When African institutions host and govern high-containment laboratories, they reshape global collaboration from one based on extraction to one based on partnership and shared authority.
Governance, safety, and public trust
Sensitivity: Official Use
BSL-4 laboratories raise legitimate concerns around safety, dual-use risks, environmental
impact, and public trust. These concerns must be addressed directly. Strong biosafety legislation, independent oversight, transparency, and meaningful engagement with surrounding communities
are essential.
Here, Africa has an opportunity to set high standards from the outset, embedding accountability into continental and regional frameworks rather than retrofitting it after crises occur.
Building the backbone of sovereignty
In the end, global health sovereignty is about choice. It is about the ability to act without waiting, to decide without deferring, and to protect populations without pleading for access. BSL-4 laboratories are not monuments to scientific ambition. They are part of the backbone of credible
outbreak preparedness.
The African Union should treat high-containment capacity as a strategic priority and pursue it at the regional level with seriousness and discipline. Ghana, through GoldBod, has an opportunity to show how extractive wealth can be converted into infrastructure that safeguards health far beyond national borders.
Africa does not need more laboratories everywhere. It needs the right laboratories, in the right places, governed in the right way. Global health sovereignty will not be declared. It will be built.
Author: Dr Selorm Avumegah, UK
Email: Selorm.Avumegah1@outlook.com Substack: https://diseasechaser.substack.com/
LinkedIn: https://www.linkedin.com/in/michael-selorm-avumegah-phd-06227842
Sensitivity: Official Use
Follow our WhatsApp Channel now! https://whatsapp.com/channel/0029VbAjG7g3gvWajUAEX12Q
